Back to results
US 8,986,672 B2Granted
Use of mutant Herpes Simplex Virus-2 for cancer therapy
AssigneeUniversity of Houston
InventorsXiaoliu Zhang, Fu Xinping
Life of this patent
Estimating the term…
Abstract
The present invention is directed to the composition and use of a modified Herpes Simplex Virus Type 2 (HSV-2) as a medicament in the treatment of cancer. The modified HSV-2 has fusogenic activity, and comprises a modified/mutated ICP 10 polynucleotide encoding a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity.
Claims6
A method of selectively killing cancer cells in a subject in need thereof, the method comprising:
- intratumorally or systemically administering to the subject in need thereof an effective amount of a fusogenic mutant Herpes Simplex Virus Type 2 (HSV-2), wherein the fusogenic mutant HSV-2 comprises a modified ICP10 coding region lacking nucleotides 1 to 1204 of an endogenous ICP10 coding region, wherein said fusogenic mutant HSV-2 comprises the modified ICP10 operably linked to an endogenous or a constitutive promoter and expresses a modified ICP10 polypeptide that lacks protein kinase (PK) activity but retains ribonucleotide reductase activity, and
- wherein said administration provides for selective killing of cancer cells by direct cytolysis and syncytia formation in cells that are susceptible to replication of the fusogenic mutant HSV-2.
Dependencies are inferred from the claim text.